ARTICLE | Politics & Policy
FDA extends window for off-label discussion
December 15, 2016 1:21 AM UTC
FDA will extend the window for stakeholders to comment on issues related to off-label communications concerning FDA-approved medical products. The agency will now accept comments until April 10, 2017, extending the comment period by 90 days...